pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects

pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects

Side effects often limit the use of doxorubicin (DOX) in cancer treatment. We have recently developed a nanostructured lipid carrier (NLC) formulation for synergistic chemotherapy, encapsulating DOX and the anticancer adjuvants docosahexaenoic acid (DHA) and α-tocopherol succinate (TS). Hydrophobic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Eduardo Burgarelli Lages, Renata Salgado Fernandes, Marina Mol Sena Andrade, Nitchawat Paiyabhroma, Renata Barbosa de Oliveira, Christian Fernandes, Geovanni Dantas Cassali, Pierre Sicard, Sylvain Richard, André Luís Branco de Barros, Lucas Antônio Miranda Ferreira
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Doxorubicin
Nanomedicine
Ion-pairing
Amide
Hydrazone
Antitumor activity
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/ab30badd949049e1a663721747a3b7e3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/ab30badd949049e1a663721747a3b7e3

Ejemplares similares